Ginseng reverses established cardiomyocyte hypertrophy and postmyocardial infarction-induced hypertrophy and heart failure

Circulation: Heart Failure

Volumn 5, Issue 4, 2012, Pages 504-514

  Moey, Melissa ^a   Gan, Xiaohong T ^a   Huang, Cathy Xiaoling ^a   Rajapurohitam, Venkatesh ^a   Martínez Abundis, Eduardo ^a   Lui, Edmund M K ^a   Karmazyn, Morris ^a  

^a WESTERN UNIVERSITY   (Canada)

Author keywords

Calcineurin; Cardiomegaly; Heart failure; NFAT transcription factors; Panax; Remodeling

Indexed keywords

CALCINEURIN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; FIBRONECTIN; GINSENG EXTRACT; TRANSCRIPTION FACTOR NFAT3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL SURFACE; CONTROLLED STUDY; CORONARY ARTERY LIGATION; ECHOCARDIOGRAPHY; GENE EXPRESSION; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; HEMODYNAMIC PARAMETERS; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BLOOD PRESSURE; CALCINEURIN; CARDIOMEGALY; CARDIOTONIC AGENTS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; HEART FAILURE; HEART RATE; MALE; MYOCARDIAL INFARCTION; MYOCYTES, CARDIAC; NFATC TRANSCRIPTION FACTORS; PANAX; PLANT PREPARATIONS; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 84864594007     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.112.967489     Document Type: Article

References (34)

1. World Health Organization. Cardiovascular diseases (CVDs). Fact sheet No. 317. September 2011. World Health Organization Web site. http://www.who.int/ mediacentre/factsheets/fs317/en/index.html. Accessed November 2011.
2. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, Carnethon MR, Dai S, de Simone G, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Greenlund KJ, Hailpern SM, Heit JA, Ho PM, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, McDermott MM, Meigs JB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Rosamond WD, Sorlie PD, Stafford RS, Turan TN, Turner MB, Wong ND, Wylie-Rosett J; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2011 update: a report from the American Heart Association [published correction in Circulation. 2011;123:e240]. Circulation. 2011;123:e18-e209.
3. Krum H, Teerlink JR. Medical therapy for chronic heart failure. Lancet. 2011;378:713-721.
4. Rouleau JL. New and emerging drugs and device therapies for chronic heart failure in patients with systolic ventricular dysfunction. Can J Cardiol. 2011;27:296-301.
5. Jessup M, Brozena M. Heart failure. N Engl J Med. 2003;348:2007-2018.
6. Hellawel JL, Margulies KB. Myocardial reverse remodeling. Cardiovasc Ther. 2010;30:172-181.
7. Tamargo J, López-Sendón J. Novel therapeutic targets for the treatment of heart failure. Nat Rev Drug Discov. 2011;10:536-555.
8. Karmazyn M, Moey M, Gan XT. Therapeutic potential of ginseng for the management of cardiovascular disorders. Drugs. 2011;71:1989-2008.
9. Guo J, Gan XT, Haist JV, Rajapurohitam V, Zeidan A, Faruq NS, Karmazyn M. Ginseng inhibits cardiomyocyte hypertrophy and heart failure via NHE-1 inhibition and attenuation of calcineurin activation. Circ Heart Fail. 2011;4:79-88.
10. Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J, Grant SR, Olson EN. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell. 1998;93:215-228.
11. Frey N, Olson EN. Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol. 2003;65:45-79.
12. Berry JM, Le V, Rotter D, Battiprolu PK, Grinsfelder B, Tannous P, Burchield JS, Czubryt M, Backs J, Olson EN, Rothermel BA, Hill JA. Reversibility of adverse, calcineurin-dependent cardiac remodeling. Circ Res. 2011;109:407-417.
13. Moey M, Rajapurohitam V, Zeidan A, Karmazyn M. Ginseng (Panax quinquefolius) attenuates leptin-induced ventricular cardiac hypertrophy through inhibition of the p115RhoGEF-RhoA/ROCK-dependent MAPK pathway activation. J Pharm Exp Ther. 2011;339:1-11.
14. Noursadeghi M, Tsang J, Haustein T, Miller RF, Chain BM, Katz DR. Quantitative imaging assay for NF-kappaB nuclear translocation in primary human macrophages. J Immunol Methods. 2008;329:194-200.
15. Azike CG, Charpentier PA, Jirui H, Pei H, Lui EMK. The yin and yang actions of North American ginseng root in modulating the immune function of macrophages. Chin Med. 2011;6:21-32.
16. Goldstein B. Ginseng: its history, dispersion and folk tradition. Am J Chin Med. 1975;3:223-334.
17. Chu SF, Zhang JT. New achievements in ginseng research and its future prospects. Chin J Integr Med. 2009;15:403-408.
18. Yoshida H, Karmazyn M. Na(+)/H(+) exchange inhibition attenuates hypertrophy and heart failure in 1-wk postinfarction rat myocardium. Am J Physiol Heart Circ Physiol. 2000;278:H300-H304.
19. Purdham DM, Rajapurohitam V, Zeidan A, Huang C, Gross GJ, Karmazyn M. A neutralizing leptin receptor antibody mitigates hypertrophy and hemodynamic dysfunction in the postinfarcted rat heart. Am J Physiol Heart Circ Physiol. 2008;295:H441-H446.
20. Liu YH, Yang XP, Nass O, Sabbah HN, Peterson E, Carretero OA. Chronic heart failure induced by coronary artery ligation in Lewis inbred rats. Am J Physiol Heart Circ Physiol. 1997;272:H722-H727.
21. Frey N, Katus HA, Olson EN, Hill JA. Hypertrophy of the heart: a new therapeutic target? Circulation. 2004;109:1580-1589.
22. Leenders JJ, Pinto YM, Creemers EE. Tapping the brake on cardiac growth-endogenous repressors of hypertrophic signaling. J Mol Cell Cardiol. 2011;51:156-167.
23. Taigen T, De Windt LJ, Lim HW, Molkentin JD. Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy. Proc Natl Acad Sci U S A. 2000;97:1196-1201.
24. Takeda Y, Yoneda T, Demura M, Usukura M, Mabuchi H. Calcineurin inhibition attenuates mineralocorticoid-induced cardiac hypertrophy. Circulation. 2002;105:677-679.
25. Nakamura TY, Iwata Y, Arai Y, Komamura K, Wakabayashi S. Activation of Na+/H+ exchanger 1 is sufficient to generate Ca2+ signals that induce cardiac hypertrophy and heart failure. Circ Res. 2008;103: 891-899.
26. Yamada T, Nagata K, Cheng XW, Obata K, Saka M, Miyachi M, Naruse K, Nishizawa T, Noda A, Izawa H, Kuzuya M, Okumura K, Murohara T, Yokota M. Long-term administration of nifedipine attenuates cardiac remodeling and diastolic heart failure in hypertensive rats. Eur J Pharmacol. 2009;615:163-170.
27. Chemaly ER, Hadri L, Zhang S, Kim M, Kohlbrenner E, Sheng J, Liang L, Chen J, K-Raman P, Hajjar RJ, Lebeche D. Long-term in vivo resistin overexpression induces myocardial dysfunction and remodeling in rats. J Mol Cell Cardiol. 2011;51:144-155.
28. Jia L, Zhao Y. Current evaluation of the millennium phytomedicine- ginseng (I): etymology, pharmacognosy, phytochemistry, market and regulations. Curr Med Chem. 2009;16:2475-2484.
29. Qi LW, Wang CZ, Yuan CS. Isolation and analysis of ginseng: advances and challenges. Nat Prod Rep. 2011;28:467-495.
30. Park C-S, Yoo M-H, Noh K-H, Oh D-K. Biotransformation by hydrolyzing the sugar moieties of ginsenosides using microbial glycosidases. Appl Microbiol Biotechnol. 2010;87: 9-19.
31. Qian T, Cai Z. Biotransformation of ginsenosdies Rb1, Rg3 and Rh2 in rat gastrointestinal tracts. Chin Med. 2010;5:19-27.
32. MERIT-HT Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001-2007.
33. Groenning BA, Nilsson JC, Sondergaard L, Fritz-Hansen T, Larsson HB, Hildebrandt PR. Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure. J Am Coll Cardiol. 2000;36:2072-2080.
34. Birks EJ, George RS, Hedger M, Bahrami T, Wilton P, Bowles CT, Webb C, Bougard R, Amrani M, Yacoub MH, Dreyfus G, Khaghani A. Reversal of severe heart failure with a continuous-flow left ventricular assist device and pharmacological therapy: a prospective study. Circulation. 2011;123:381-390.